Antibody blockade of CLEC12A delays EAE onset and attenuates disease severity by impairing myeloid cell CNS infiltration and restoring positive immunity

Scientific Reports

Volumn 7, Issue 1, 2017, Pages

  Sagar, DIvya ^a   Singh, Narendra P ^b   Ginwala, Rashida ^a   Huang, Xiaofang ^d   Philip, Ramila ^d   Nagarkatti, Mitzi ^b,c   Nagarkatti, Prakash ^b   Neumann, Konstantin ^e   Ruland, Jürgen ^e   Andrews, Allison M ^f   Ramirez, Servio H ^f   Khan, Zafar K ^a   Jain, Pooja ^a  

^a DREXEL UNIVERSITY COLLEGE OF MEDICINE   (United States)

^b UNIVERSITY OF SOUTH CAROLINA SCHOOL OF MEDICINE   (United States)

^c WJB Dorn VA Medical Center   (United States)

^d Immunotope Inc   (United States)

^e TECHNICAL UNIVERSITY OF MUNICH   (Germany)

^f TEMPLE UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BLOCKING ANTIBODY; CLEC12A PROTEIN, MOUSE; LECTIN; LECTIN RECEPTOR; MONOCYTE CHEMOTACTIC PROTEIN 1; PROTEIN BINDING; PROTEIN TYROSINE PHOSPHATASE SHP 1; PROTEIN TYROSINE PHOSPHATASE SHP 2; PTPN11 PROTEIN, MOUSE;

ANIMAL; ANTAGONISTS AND INHIBITORS; BIOLOGICAL MODEL; BONE MARROW CELL; CENTRAL NERVOUS SYSTEM; DENDRITIC CELL; DRUG EFFECT; EXPERIMENTAL AUTOIMMUNE ENCEPHALOMYELITIS; GENETICS; IMMUNITY; IMMUNOLOGY; KNOCKOUT MOUSE; METABOLISM; MOUSE; PATHOLOGY; PHENOTYPE; RECURRENT DISEASE; SEVERITY OF ILLNESS INDEX; SIGNAL TRANSDUCTION; TRANSENDOTHELIAL AND TRANSEPITHELIAL MIGRATION; VASCULAR ENDOTHELIUM;

ANIMALS; ANTIBODIES, BLOCKING; CENTRAL NERVOUS SYSTEM; CHEMOKINE CCL2; DENDRITIC CELLS; ENCEPHALOMYELITIS, AUTOIMMUNE, EXPERIMENTAL; ENDOTHELIUM, VASCULAR; IMMUNITY; LECTINS; LECTINS, C-TYPE; MICE; MICE, KNOCKOUT; MODELS, BIOLOGICAL; MYELOID CELLS; PHENOTYPE; PROTEIN BINDING; PROTEIN TYROSINE PHOSPHATASE, NON-RECEPTOR TYPE 11; PROTEIN TYROSINE PHOSPHATASE, NON-RECEPTOR TYPE 6; RECEPTORS, MITOGEN; RECURRENCE; SEVERITY OF ILLNESS INDEX; SIGNAL TRANSDUCTION; TRANSENDOTHELIAL AND TRANSEPITHELIAL MIGRATION;

EID: 85020204504     PISSN: None     EISSN: 20452322     Source Type: Journal    
DOI: 10.1038/s41598-017-03027-x     Document Type: Article

References (62)

1. Loma, I. & Heyman, R. Multiple sclerosis: pathogenesis and treatment. Curr Neuropharmacol 9, 409-416, doi:10.2174/157015911796557911 (2011).
2. Sagar, D. et al. Dendritic cell CNS recruitment correlates with disease severity in EAE via CCL2 chemotaxis at the blood-brain barrier through paracellular transmigration and ERK activation. J Neuroinflammation 9, 245, doi:10.1186/1742-2094-9-245 (2012).
3. Sosa, R. A., Murphey, C., Ji, N., Cardona, A. E. & Forsthuber, T. G. The kinetics of myelin antigen uptake by myeloid cells in the central nervous system during experimental autoimmune encephalomyelitis. J Immunol 191, 5848-5857, doi:10.4049/jimmunol.1300771 (2013).
4. Yednock, T. A. et al. Prevention of experimental autoimmune encephalomyelitis by antibodies against alpha 4 beta 1 integrin. Nature 356, 63-66, doi:10.1038/356063a0 (1992).
5. Boster, A. L. et al. Lessons learned from fatal progressive multifocal leukoencephalopathy in a patient with multiple sclerosis treated with natalizumab. JAMA Neurol 70, 398-402, doi:10.1001/jamaneurol.2013.1960 (2013).
6. Tortorella, C., Direnzo, V., D'Onghia, M. & Trojano, M. Brainstem PML lesion mimicking MS plaque in a natalizumab-treated MS patient. Neurology 81, 1470-1471, doi:10.1212/WNL.0b013e3182a84179 (2013).
7. Brocke, S., Piercy, C., Steinman, L., Weissman, I. L. & Veromaa, T. Antibodies to CD44 and integrin alpha4, but not L-selectin, prevent central nervous system inflammation and experimental encephalomyelitis by blocking secondary leukocyte recruitment. Proc Natl Acad Sci USA 96, 6896-6901 (1999).
8. de Andres, C. et al. Long-term decrease in VLA-4 expression and functional impairment of dendritic cells during natalizumab therapy in patients with multiple sclerosis. PLoS One 7, e34103, doi:10.1371/journal.pone.0034103 (2012).
9. Rahman, S. et al. Unique Cytokine/Chemokine Signatures for HIV-1 and HCV Mono-infection versus Co-infection as Determined by the Luminex(R) Analyses. J Clin Cell Immunol 2, doi:10.4172/2155-9899.1000104 (2011).
10. Mindur, J. E., Ito, N., Dhib-Jalbut, S. & Ito, K. Early treatment with anti-VLA-4 mAb can prevent the infiltration and/or development of pathogenic CD11b+CD4+ T cells in the CNS during progressive EAE. PLoS One 9, e99068, doi:10.1371/journal.pone.0099068 (2014).
11. Dijkstra, C. D., De Groot, C. J. & Huitinga, I. The role of macrophages in demyelination. J Neuroimmunol 40, 183-188 (1992).
12. Moreno, M. et al. Conditional ablation of astroglial CCL2 suppresses CNS accumulation of M1 macrophages and preserves axons in mice with MOG peptide EAE. J Neurosci 34, 8175-8185, doi:10.1523/JNEUROSCI.1137-14.2014 (2014).
13. Vainchtein, I. D. et al. In acute experimental autoimmune encephalomyelitis, infiltrating macrophages are immune activated, whereas microglia remain immune suppressed. Glia 62, 1724-1735, doi:10.1002/glia.22711 (2014).
14. Clarkson, B. D. et al. Mapping the accumulation of co-infiltrating CNS dendritic cells and encephalitogenic T cells during EAE. J Neuroimmunol, doi:10.1016/j.jneuroim.2014.09.016 (2014).
15. Dittel, B. N., Visintin, I., Merchant, R. M. & Janeway, C. A. Jr. Presentation of the self antigen myelin basic protein by dendritic cells leads to experimental autoimmune encephalomyelitis. J Immunol 163, 32-39 (1999).
16. Gautam, A. M. & Glynn, P. Lewis rat lymphoid dendritic cells can efficiently present homologous myelin basic protein to encephalitogenic lymphocytes. J Neuroimmunol 22, 113-121 (1989).
17. Hatterer, E., Touret, M., Belin, M. F., Honnorat, J. & Nataf, S. Cerebrospinal fluid dendritic cells infiltrate the brain parenchyma and target the cervical lymph nodes under neuroinflammatory conditions. PLoS One 3, e3321, doi:10.1371/journal.pone.0003321 (2008).
18. Wlodarczyk, A., Lobner, M., Cedile, O. & Owens, T. Comparison of microglia and infiltrating CD11c(+) cells as antigen presenting cells for T cell proliferation and cytokine response. J Neuroinflammation 11, 57, doi:10.1186/1742-2094-11-57 (2014).
19. Wu, G. F. et al. Limited sufficiency of antigen presentation by dendritic cells in models of central nervous system autoimmunity. J Autoimmun 36, 56-64, doi:10.1016/j.jaut.2010.10.006 (2011).
20. Jain, P., Coisne, C., Enzmann, G., Rottapel, R. & Engelhardt, B. Alpha4beta1 integrin mediates the recruitment of immature dendritic cells across the blood-brain barrier during experimental autoimmune encephalomyelitis. J Immunol 184, 7196-7206, doi:10.4049/jimmunol.0901404 (2010).
21. Sagar, D. et al. Mechanisms of Dendritic Cell Trafficking Across the Blood-brain Barrier. J Neuroimmune Pharmacol, doi:10.1007/s11481-011-9302-7 (2011).
22. Cambi, A. & Figdor, C. G. Dual function of C-type lectin-like receptors in the immune system. Curr Opin Cell Biol 15, 539-546 (2003).
23. Kanazawa, N. Dendritic cell immunoreceptors: C-type lectin receptors for pattern-recognition and signaling on antigen-presenting cells. J Dermatol Sci 45, 77-86, doi:10.1016/j.jdermsci.2006.09.001 (2007).
24. Dominguez, P. M. & Ardavin, C. Differentiation and function of mouse monocyte-derived dendritic cells in steady state and inflammation. Immunol Rev 234, 90-104, doi:10.1111/j.0105-2896.2009.00876.x (2010).
25. Soilleux, E. J. et al. Constitutive and induced expression of DC-SIGN on dendritic cell and macrophage subpopulations in situ and in vitro. J Leukoc Biol 71, 445-457 (2002).
26. Springer, T. A. Traffic signals for lymphocyte recirculation and leukocyte emigration: the multistep paradigm. Cell 76, 301-314 (1994).
27. D'Mello, C. et al. P-selectin-mediated monocyte-cerebral endothelium adhesive interactions link peripheral organ inflammation to sickness behaviors. J Neurosci 33, 14878-14888, doi:10.1523/JNEUROSCI.1329-13.2013 (2013).
28. Engelhardt, B. Immune cell entry into the central nervous system: involvement of adhesion molecules and chemokines. J Neurol Sci 274, 23-26, doi:10.1016/j.jns.2008.05.019 (2008).
29. Sreeramkumar, V. et al. Coordinated and unique functions of the E-selectin ligand ESL-1 during inflammatory and hematopoietic recruitment in mice. Blood 122, 3993-4001, doi:10.1182/blood-2013-07-514497 (2013).
30. Clarkson, B. D. et al. CCR2-Dependent Dendritic Cell Accumulation in the Central Nervous System during Early Effector Experimental Autoimmune Encephalomyelitis Is Essential for Effector T Cell Restimulation In Situ and Disease Progression. J Immunol. doi:10.4049/jimmunol.1401320 (2014).
31. Arjmandi, A., Liu, K. & Dorovini-Zis, K. Dendritic cell adhesion to cerebral endothelium: role of endothelial cell adhesion molecules and their ligands. J Neuropathol Exp Neurol 68, 300-313, doi:10.1097/NEN.0b013e31819a8dd1 (2009).
32. Weksler, B. B. et al. Blood-brain barrier-specific properties of a human adult brain endothelial cell line. FASEB J 19, 1872-1874, doi:10.1096/fj.04-3458fje (2005).
33. Sathiyanadan, K., Coisne, C., Enzmann, G., Deutsch, U. & Engelhardt, B. PSGL-1 and E/P-selectins are essential for T-cell rolling in inflamed CNS microvessels but dispensable for initiation of EAE. Eur J Immunol 44, 2287-2294, doi:10.1002/eji.201344214 (2014).
34. Chou, H. C. et al. WIP regulates the stability and localization of WASP to podosomes in migrating dendritic cells. Curr Biol 16, 2337-2344, doi:10.1016/j.cub.2006.10.037 (2006).
35. Pashenkov, M. et al. Elevated expression of CCR5 by myeloid (CD11c+) blood dendritic cells in multiple sclerosis and acute optic neuritis. Clin Exp Immunol 127, 519-526 (2002).
36. Greter, M. et al. Dendritic cells permit immune invasion of the CNS in an animal model of multiple sclerosis. Nat Med 11, 328-334, doi:10.1038/nm1197 (2005).
37. Miller, S. D., McMahon, E. J., Schreiner, B. & Bailey, S. L. Antigen presentation in the CNS by myeloid dendritic cells drives progression of relapsing experimental autoimmune encephalomyelitis. Ann N Y Acad Sci 1103, 179-191, doi:10.1196/annals.1394.023 (2007).
38. Martinez-Quiles, N. et al. WIP regulates N-WASP-mediated actin polymerization and filopodium formation. Nat Cell Biol 3, 484-491, doi:10.1038/35074551 (2001).
39. Cambi, A., Koopman, M. & Figdor, C. G. How C-type lectins detect pathogens. Cell Microbiol 7, 481-488, doi:10.1111/j.1462-5822.2005.00506.x (2005).
40. Lahoud, M. H. et al. The C-type lectin Clec12A present on mouse and human dendritic cells can serve as a target for antigen delivery and enhancement of antibody responses. J Immunol 182, 7587-7594, doi:10.4049/jimmunol.0900464 (2009).
41. Bakker, A. B. et al. C-type lectin-like molecule-1: a novel myeloid cell surface marker associated with acute myeloid leukemia. Cancer Res 64, 8443-8450, doi:10.1158/0008-5472.CAN-04-1659 (2004).
42. Marshall, A. S. et al. Identification and characterization of a novel human myeloid inhibitory C-type lectin-like receptor (MICL) that is predominantly expressed on granulocytes and monocytes. J Biol Chem 279, 14792-14802, doi:10.1074/jbc.M313127200 (2004).
43. Pyz, E. et al. Characterisation of murine MICL (CLEC12A) and evidence for an endogenous ligand. Eur J Immunol 38, 1157-1163, doi:10.1002/eji.200738057 (2008).
44. Neumann, K. et al. Clec12a is an inhibitory receptor for uric acid crystals that regulates inflammation in response to cell death. Immunity 40, 389-399, doi:10.1016/j.immuni.2013.12.015 (2014).
45. Redelinghuys, P. et al. MICL controls inflammation in rheumatoid arthritis. Ann Rheum Dis, doi:10.1136/annrheumdis-2014-206644 (2015).
46. Lyons, J. A., San, M., Happ, M. P. & Cross, A. H. B cells are critical to induction of experimental allergic encephalomyelitis by protein but not by a short encephalitogenic peptide. Eur J Immunol 29, 3432-3439, doi:10.1002/(SICI)1521-4141(199911) 29:11 3.0.CO;2-2 (1999).
47. Scott, G. S. et al. Therapeutic intervention in experimental allergic encephalomyelitis by administration of uric acid precursors. Proc Natl Acad Sci U S A 99, 16303-16308, doi:10.1073/pnas.212645999 (2002).
48. Kean, R. B., Spitsin, S. V., Mikheeva, T., Scott, G. S. & Hooper, D. C. The peroxynitrite scavenger uric acid prevents inflammatory cell invasion into the central nervous system in experimental allergic encephalomyelitis through maintenance of blood-central nervous system barrier integrity. J Immunol 165, 6511-6518 (2000).
49. Moccia, M. et al. Uric acid in relapsing-remitting multiple sclerosis: a 2-year longitudinal study. J Neurol 262, 961-967, doi:10.1007/s00415-015-7666-y (2015).
50. Hooper, D. C. et al. Uric acid, a peroxynitrite scavenger, inhibits CNS inflammation, blood-CNS barrier permeability changes, and tissue damage in a mouse model of multiple sclerosis. FASEB J 14, 691-698 (2000).
51. Sotgiu, S. et al. Serum uric acid and multiple sclerosis. Neurol Sci 23, 183-188, doi:10.1007/s100720200059 (2002).
52. Kutzing, M. K. & Firestein, B. L. Altered uric acid levels and disease states. J Pharmacol Exp Ther 324, 1-7, doi:10.1124/jpet.107.129031 (2008).
53. Barrow, A. D. & Trowsdale, J. You say ITAM and I say ITIM, let's call the whole thing off: the ambiguity of immunoreceptor signalling. Eur J Immunol 36, 1646-1653, doi:10.1002/eji.200636195 (2006).
54. Pasquet, J. M. et al. Evidence of a role for SHP-1 in platelet activation by the collagen receptor glycoprotein VI. J Biol Chem 275, 28526-28531, doi:10.1074/jbc.M001531200 (2000).
55. Wang, Q., Downey, G. P., Herrera-Abreu, M. T., Kapus, A. & McCulloch, C. A. SHP-2 modulates interleukin-1-induced Ca2+ flux and ERK activation via phosphorylation of phospholipase Cgamma1. J Biol Chem 280, 8397-8406, doi:10.1074/jbc.M410462200 (2005).
56. Hertzenberg, D. et al. Developmental maturation of innate immune cell function correlates with susceptibility to central nervous system autoimmunity. Eur J Immunol 43, 2078-2088, doi:10.1002/eji.201343338 (2013).
57. Chen, C. H. et al. Dendritic-cell-Associated C-type lectin 2 (DCAL-2) alters dendritic-cell maturation and cytokine production. Blood 107, 1459-1467, doi:10.1182/blood-2005-08-3264 (2006).
58. Rhee, I., Zhong, M. C., Reizis, B., Cheong, C. & Veillette, A. Control of dendritic cell migration, T cell-dependent immunity, and autoimmunity by protein tyrosine phosphatase PTPN12 expressed in dendritic cells. Mol Cell Biol 34, 888-899, doi:10.1128/MCB.01369-13 (2014).
59. Clarkson, B. D. et al. Mapping the accumulation of co-infiltrating CNS dendritic cells and encephalitogenic T cells during EAE. J Neuroimmunol 277, 39-49, doi:10.1016/j.jneuroim.2014.09.016 (2014).
60. Zhou, J., Nagarkatti, P., Zhong, Y. & Nagarkatti, M. Immune modulation by chondroitin sulfate and its degraded disaccharide product in the development of an experimental model of multiple sclerosis. J Neuroimmunol 223, 55-64, doi:10.1016/j. jneuroim.2010.04.002 (2010).
61. Singh, N. P., Hegde, V. L., Hofseth, L. J., Nagarkatti, M. & Nagarkatti, P. Resveratrol (trans-3,5,4?-trihydroxystilbene) ameliorates experimental allergic encephalomyelitis, primarily via induction of apoptosis in T cells involving activation of aryl hydrocarbon receptor and estrogen receptor. Mol Pharmacol 72, 1508-1521, doi:10.1124/mol.107.038984 (2007).
62. Guan, H., Nagarkatti, P. S. & Nagarkatti, M. CD44 Reciprocally regulates the differentiation of encephalitogenic Th1/Th17 and Th2/regulatory T cells through epigenetic modulation involving DNA methylation of cytokine gene promoters, thereby controlling the development of experimental autoimmune encephalomyelitis. J Immunol 186, 6955-6964, doi:10.4049/jimmunol.1004043 (2011).